Yungjin Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Yungjin Pharm is a South Korean pharmaceutical company that develops and supplies medicines for human health.
Its products reach patients and healthcare providers through the domestic pharmaceutical market. The company is listed on KOSPI, Korea's main stock exchange. The filing does not provide sufficient detail to identify a single dominant structural fact about its business model or product mix.
Summary is AI-generated and may contain errors · figures from DART filings
Yungjin Pharm in five facts
What does Yungjin Pharm do?
Yungjin Pharm is a South Korean pharmaceutical company that develops and supplies medicines for human health.
Where is Yungjin Pharm listed and in which sector?
Yungjin Pharm (Korean name: 영진약품) trades under KRX code 003520 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Yungjin Pharm?
Its market capitalisation was US$138.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Yungjin Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Yungjin Pharm reported revenue of US$191.9M, operating profit of US$2.6M and a net loss of US$171.8K, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 0.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
Yungjin Pharm updated a previously disclosed supply contract with MYLAN SEIYAKU LTD, now worth US$9.15M, about 5.5% of its recent annual revenue, running through Oct 2027.
Supply contract · Oct 8 - DisclosureSep 1
- [Amended] Supply contract signed
Yungjin Pharm updated a previously disclosed supply contract with Zhongshan Belling Biotechnology Co., Ltd., now worth US$45.3M, about 27.32% of its recent annual revenue, running through Aug 2036.
Supply contract · Aug 12 - Operating results (preliminary) (fair disclosure)
Yungjin Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$43.3M (−1.5% year on year), an operating loss of US$1.05M (from a profit a year earlier) and a net loss of US$1.71M (from a profit a year earlier).
Earnings · Jul 31 - Operating results (preliminary) (fair disclosure)
Yungjin Pharm filed provisional (unaudited) separate results for Q1 2026: revenue of US$44.1M (−0.5% year on year), an operating loss of US$1.21M (from a profit a year earlier) and a net loss of US$1.58M (from a profit a year earlier).
Earnings · May 6 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 16